DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the KWALITY PHARMACEUTICALS L (KPL) share price today?

KWALITY PHARMACEUTICALS L (KPL) is trading at ₹2,702 on the NSE, down 4.08% on the day. Source: DocStoX.

What is the PE ratio of KWALITY PHARMACEUTICALS L?

KWALITY PHARMACEUTICALS L has a price-to-earnings (PE) ratio of 41.6 in the Healthcare sector.

What is the market capitalisation of KWALITY PHARMACEUTICALS L?

KWALITY PHARMACEUTICALS L has a market capitalisation of approximately ₹2,812 crore.

KWALITY PHARMACEUTICALS L

KPL·NSE·Healthcare

₹2,702.00▼ -114.90 (-4.08%)

Healthcare · Pharmaceuticals & Biotechnology

Revenue compounding 26% a year

Day₹2689.20

₹2859.90

52W₹1561

₹289086%

Open

₹2816.90

High

₹2859.90

Low

₹2689.20

Prev Close

₹2816.90

Volume

23.5K

VWAP

₹2722.44

Snapshot

Key fundamentals

Market Cap

₹2,812 Cr

P/E Ratio

41.63Expensive

P/B Ratio

8.58

EPS

₹64.91

Book Value

₹320.00

ROE

22.80%Strong

ROCE

24.00%Efficient

Dividend Yield

N/A

Debt / Equity

N/A

Face Value

₹10.00

52W High

₹2890.30

52W Low

₹1561.00

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹518

▼ 80.8%downside

Trading at ₹2,702 — 81% above our estimate

BearFair valueBull

₹440₹518₹684

/100

Business quality — Solid

Growth 100Profitability 76Efficiency 40Valuation 21

Plain English

Our view

Revenue compounding 26% a year
Strong returns on equity (23%)
Fundamental red flags (Piotroski 3/9)

Strengths

Strong returns on equity (23%)
Capital is working hard (ROCE 24%)
Revenue compounding 26% over 3 years
Profit growing 52% a year

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

23% ROE fading to 13% over ~10 yrs, on ₹320 book

₹472

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹684

Analyst target

No analyst coverage

—

Blended fair value₹518

What the numbers say

Investment thesis

Bull case

Strong returns on equity (23%)
Capital is working hard (ROCE 24%)
Revenue compounding 26% over 3 years
Profit growing 52% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

41.6Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

22.8%Strong

Above 15% is considered healthy for Indian equities

ROCE

24.0%Efficient

Above 18% means capital is working hard

Debt/Eq

—

Mkt Cap

₹2,812 Cr

P/B

8.58

EPS

₹64.91

Div Yield

—

What changed

Recent changes

Foreign investors+2.3% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 41.6×

Growth

Strong

+26% rev CAGR

Profitability

Excellent

22.8% ROE

Financial health

N/A

No debt data

Momentum

N/A

No technicals

Today

Trading activity

Delivery %42.4%

Turnover₹639.15L Cr

Trades4,728

VWAP₹2722.44

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+26.1%

+13.9%

10Y

+21.1%

Profit

+52.2%

+34.9%

10Y

+52.3%

EPS

+51.5%

+34.8%

10Y

+45.3%

Profile

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 35.0% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 18.2%
Company's median sales growth is 27.4% of last 10 years

Watch-outs

Cons

Stock is trading at 8.13 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has high debtors of 203 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 2.29 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

55%

Promoter

Promoters

54.9%+0.05

Public

42.0%-2.34

FII / FPI

2.8%+2.29

DII

0.4%+0.03

Total shareholders

10,555

Quarterly trend

Ownership over time

Q4 FY26

Promoter54.87%

FII2.79%

DII0.36%

Public41.99%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]